A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Latest Information Update: 22 Feb 2024
At a glance
- Drugs DZ-002 (Primary)
- Indications Lymphoma; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Da Zen Theranostics
- 15 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Mar 2025.
- 15 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2025.
- 08 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Feb 2024.